ABCL · Nasdaq · CIK 0001703057

AbCellera Biologics Inc.

AbCellera Biologics Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Aug 24, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $75.1M and net income of -$146.4M, according to its XBRL data on EDGAR. Its EDGAR record lists 22 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$75.1M
Net income, FY2025
-$146.4M
Form 4 filings on record, past 12 months
22

Company overview

Legal name (as filed)
AbCellera Biologics Inc.
Ticker
ABCL
SEC Central Index Key (CIK)
0001703057
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
VANCOUVER, British Columbia, Canada
State or country of incorporation
British Columbia, Canada
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1562 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from AbCellera Biologics Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$375.2MFY2021$485.4MFY2022$38.0MFY2023$28.8MFY2024$75.1MFY2025
Net income
$153.5MFY2021$158.5MFY2022-$146.4MFY2023-$162.9MFY2024-$146.4MFY2025
ABCL annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$375.2M$485.4M$38.0M$28.8M$75.1M
Net income$153.5M$158.5M-$146.4M-$162.9M-$146.4M
Diluted EPS$0.48$0.50-$0.51-$0.55-$0.49
Total assets$1.3B$1.5B$1.5B$1.4B$1.4B
Cash and equivalents$476.1M$386.5M$133.3M$156.3M$128.5M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ABCL latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 24, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 13, 20268-KMaterial agreement; Other events· period Aug 12, 2026Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Dec 31, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about AbCellera Biologics Inc., by form type:

4 ×168-K ×123 ×2424B5 ×210-Q ×2SCHEDULE 13G/A ×1ARS ×1DEFA14A ×1DEF 14A ×1S-8 ×110-K ×1
ABCL recent filings
FiledFormWhat it isOriginal
Aug 24, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 24, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 13, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026Document · Index
Aug 13, 20268-KMaterial agreement; Other events· period Aug 12, 2026Document · Index
Aug 13, 2026424B5424B5Document · Index
Aug 11, 2026424B5424B5Document · Index
Aug 10, 20268-KRegulation FD disclosure· period Aug 10, 2026Document · Index
Aug 7, 20268-KOther events· period Aug 7, 2026Document · Index
Aug 5, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 5, 20268-KResults of operations; Regulation FD disclosure· period Aug 5, 2026Document · Index
Jul 29, 20268-KOther events· period Jul 29, 2026Document · Index
Jul 6, 20268-KDirector or officer change· period Jun 30, 2026Document · Index
Jul 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jul 6, 20263Initial statement of beneficial ownership· period Jun 30, 2026Document · Index
Jul 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jun 17, 20268-KOther events· period Jun 17, 2026Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 12, 20268-KShareholder vote results· period Jun 11, 2026Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 11, 20263Initial statement of beneficial ownership· period Jun 1, 2026Document · Index
Jun 5, 20268-KDirector or officer change· period Jun 1, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
May 18, 20264Statement of changes in beneficial ownership (insider trade)· period May 14, 2026Document · Index
May 11, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 11, 20268-KResults of operations; Regulation FD disclosure· period May 11, 2026Document · Index
May 7, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 29, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 29, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Dec 31, 2025Document · Index
Mar 2, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 27, 2026Document · Index
Feb 27, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 26, 2026Document · Index
Feb 27, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 27, 2026Document · Index
Feb 24, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Feb 24, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 24, 20268-KResults of operations; Regulation FD disclosure· period Feb 24, 2026Document · Index
Jan 14, 20268-KRegulation FD disclosure· period Jan 12, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 1, 2026Document · Index

Insider filing activity

22 Form 4 filings appear in AbCellera Biologics Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001703057 and XBRL company facts. AbCellera Biologics Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.